Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms (MPN) Group Shireen Sirhan1, Lambert Busque2, Lynda Foltz3, Kuljit Grewal4, Caroline Hamm5, Nicole Laferriere6, Pierre Laneuville7, Brian Leber8, Elena Liew9, Harold J. Olney10, Jaroslav Prchal7, Anna Porwit11, Vikas Gupta12 Institution Affiliations: 1Division of Hematology, Jewish General Hospital, Montreal, Quebec; 2Hematopoiesis and Aging Research Unit, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; 3Division of Hematology, St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia; 4Faculty of Medicine, Memorial University, St. John’s, Newfoundland; 5Western University, Department of Oncology, Windsor site;, Windsor, Ontario 6Thunder Bay Regional Health Sciences, Department of Oncology, Lakehead University, Thunder Bay, Ontario; 7Department of Oncology, McGill University, Montreal, Quebec; 8Department of Medicine, Hematology and Thromboembolism, McMaster University, Hamilton, Ontario; 9Division of Hematology, University of Alberta, Edmonton, Alberta; 10Department of Hematology and Transfusional Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec; 11Department of Pathology, University Health Network, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario,12 Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario Title: Treatment Options for PV Word count: Abstract: 243 Main Manuscript: ~ 5430 References: 90 Tables: 4 Figures: 3
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms (MPN) Group Shireen Sirhan1, Lambert Busque2, Lynda Foltz3, Kuljit Grewal4, Caroline Hamm5, Nicole Laferriere6, Pierre Laneuville7, Brian Leber8, Elena Liew9, Harold J. Olney10, Jaroslav Prchal7, Anna Porwit11, Vikas Gupta12 Institution Affiliations: 1Division of Hematology, Jewish General Hospital, Montreal, Quebec; 2Hematopoiesis and Aging Research Unit, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; 3Division of Hematology, St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia; 4Faculty of Medicine, Memorial University, St. John’s, Newfoundland; 5Western University, Department of Oncology, Windsor site;, Windsor, Ontario 6Thunder Bay Regional Health Sciences, Department of Oncology, Lakehead University, Thunder Bay, Ontario; 7Department of Oncology, McGill University, Montreal, Quebec; 8Department of Medicine, Hematology and Thromboembolism, McMaster University, Hamilton, Ontario; 9Division of Hematology, University of Alberta, Edmonton, Alberta; 10Department of Hematology and Transfusional Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec; 11Department of Pathology, University Health Network, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario,12 Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario Title: Treatment Options for PV Word count: Abstract: 243 Main Manuscript: ~ 5430 References: 90 Tables: 4 Figures: 3